Drug Type CAR-T |
Synonyms antiCD19 CAR Tcell therapy Applied DNA Sciences, CD19 CARvac T cell therapy (iCell Gene Therapeutics), LinCART19 CAR T therapy Applied DNA Sciences |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Gene transference(Gene transference), T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Leukemia | Phase 1 | China | 01 Feb 2018 | |
B-Cell Leukemia | Phase 1 | China | 01 Feb 2018 | |
B-Cell Lymphoma | Phase 1 | China | 01 Feb 2018 | |
B-Cell Lymphoma | Phase 1 | China | 01 Feb 2018 | |
Acute Lymphoblastic Leukemia | Clinical | China | 08 Apr 2019 |